Patient-specific academic detailing for smoking cessation

Feasibility study

Margaret Jin PharmD MSc  Antony Gagnon PharmD  Mitchell Levine MD FRCPc MSc
Lehana Thabane MSc PhD  Christine Rodriguez MSc  Lisa Dolovich PharmD MSc

Abstract

Objective To describe and to determine the feasibility of a patient-specific academic detailing (PAD) smoking cessation (SC) program in a primary care setting.

Design Descriptive cohort feasibility study.

Setting Hamilton, Ont.

Participants Pharmacists, physicians, nurse practitioners, and their patients.

Interventions Integrated pharmacists received basic academic detailing training and education on SC and then delivered PAD to prescribers using structured verbal education and written materials. Data were collected using structured forms.

Main outcome measures Five main feasibility criteria were generated based on Canadian academic detailing programs: PAD coordinator time to train pharmacists less than 40 hours; median time of SC education per pharmacist less than 20 hours; median time per PAD session less than 60 minutes for initial visit; percentage of prescribers receiving PAD within 3 months greater than 50%; and number of new SC referrals to pharmacists at 6 months more than 10 patients per 1.0 full-time equivalent (FTE) pharmacist (total of approximately 30 patients).

Results Eight pharmacists (5.8 FTE) received basic academic detailing training and education on SC PAD. Forty-eight physicians and 9 nurse practitioners consented to participate in the study. The mean PAD coordinator training time was 29.1 hours. The median time for SC education was 3.1 hours. The median times for PAD sessions were 15 and 25 minutes for an initial visit and follow-up visit, respectively. The numbers of prescribers who had received PAD at 3 and 6 months were 50 of 64 (78.1%) and 57 of 64 (89.1%), respectively. The numbers of new SC referrals at 3 and 6 months were 11 patients per FTE pharmacist (total of 66 patients) and 34 patients per FTE pharmacist (total of 200 patients), respectively.

Conclusion This study met the predetermined feasibility criteria with respect to the management, resources, process, and scientific components. Further study is warranted to determine whether PAD is more effective than conventional academic detailing.

EDITOR’S KEY POINTS

- This study shows that patient-specific academic detailing (PAD) is feasible in a primary care setting. The high number of referrals to the pharmacists for smoking cessation (SC) after the provision of PAD shows that it might be a promising approach that moves beyond knowledge transmission to use existing clinical relationships and changes to processes within the practice setting to stimulate substantial behaviour changes.

- The results of this study can be used to plan a larger PAD study on SC in an environment where policies would encourage such a program. A large, multisite, prospective randomized study of PAD on SC would be optimal to better understand how this approach can improve medication prescribing, its effectiveness on quit rates, and related patient health outcomes.
Formation continue en pharmacothérapie spécifique au patient pour la cessation du tabagisme

Étude de faisabilité

Margaret Jin PharmD MSc  Antony Gagnon PharmD  Mitchell Levine MD FRCP MSc
Lehana Thabane MSc PhD  Christine Rodríguez MSc  Lisa Dolovich PharmD MSc

Résumé

Objectif Décrire un programme de formation continue en pharmacothérapie spécifique au patient (FPSP) pour la cessation du tabagisme (CT) et en déterminer la faisabilité dans un milieu de soins primaires.

Type d’étude Étude de cohorte descriptive sur la faisabilité.

Contexte Hamilton, en Ontario.

Participants Des pharmaciens, des médecins, des infirmières praticiennes et leurs patients.

Interventions Un groupe intégré de pharmaciens a suivi une formation de base en pharmacothérapie et un programme d’éducation en CT, puis a présenté cette même formation aux prescripteurs sous forme verbale structurée et à l’aide de matériel écrit. Les données ont été recueillies au moyen de formulaires structurés.

Principaux paramètres à l’étude On a élaboré cinq principaux critères de faisabilité en se fondant sur les programmes de formation continue en pharmacothérapie canadiens: moins de 40 heures consacrées par le coordonnateur du programme de FPSP pour former les pharmaciens; moins de 20 heures en moyenne par pharmacien pour la formation en CT; moins de 60 minutes en moyenne par séance de FPSP pour la visite initiale; plus de 50 % des prescripteurs suivant un programme de FPSP dans un délai de 3 mois; et un nombre supérieur à 10 nouveaux patients par 1,0 pharmacien équivalent temps plein (ETP) envoyés en consultation pour CT (total d’environ 30 patients).

Résultats Huit pharmaciens (5,8 ETP) ont reçu une formation en pharmacothérapie continue de base et ont suivi un programme d’éducation en CT. Quarante-huit médecins et 9 infirmières praticiennes ont consenti à participer à l’étude. Le coordonnateur du programme de FPSP a consacré en moyenne 29,1 heures pour la formation. La durée moyenne pour la formation en CT était de 3,1 heures. La visite initiale et celle de suivi pour les séances du FPSP duraient respectivement 15 et 25 minutes. Les nombres de prescripteurs ayant suivi la FPSP à 3 et à 6 mois se situaient à 50 sur 64 (78,1 %) et à 57 sur 64 (89,1 %) respectivement. Les nombres de nouvelles demandes de consultation en CT à 3 et à 6 mois s’élevaient respectivement à 11 patients par pharmacien ETP (total de 66 patients) et à 34 patients par pharmacien ETP (total de 200 patients) respectivement.

Conclusion Cette étude a satisfait aux critères de faisabilité prédéterminés en ce qui concerne la gestion, les ressources, le processus et les composantes scientifiques. Des études plus approfondies s’imposent pour déterminer si la FPSP est plus efficace que la formation continue en pharmacothérapie conventionnelle.
Patient-specific academic detailing (PAD) is a new model developed in Hamilton, Ont, that combines 2 professional services: academic detailing and pharmacist clinical services in a family practice setting. Academic detailing is a method of continuing medical education in which knowledgeable, trained health professionals meet with prescribers in their practice settings to provide one-on-one evidence-based information. One of the main goals of academic detailing programs is to provide well-balanced, objective medication information without influence from pharmaceutical companies. Thus, pharmacists are often chosen as academic detailers given their expertise in drug therapy. Academic detailing has been shown to be one of the most effective methods to improve how medications are prescribed and used; studies have examined academic detailing for prescribing antibiotics, antidepressants, benzodiazepines, nonsteroidal anti-inflammatory drugs, and diuretics for hypertension. Academic detailing has also been used to target behaviour related to the provision of smoking cessation (SC) advice.

Despite the proven benefits of academic detailing in optimizing prescribing practices, there are a number of limitations and barriers that might prevent physicians from participating in academic detailing services. These include difficulty in scheduling office time, physician preference for accessing continuing medical education in other ways, and the perception that a considerable amount of time is required for academic detailing sessions. In addition, as academic detailers might only see prescribers intermittently, the relationship between prescribers and academic detailers might take some time to develop.

Patient-specific academic detailing was developed to offset some of the limitations of academic detailing and promote pharmacists’ services in family health teams (FHTs) in Hamilton. In primary care, pharmacists are integrated within practices as consultants to review patients’ medications, identify drug-related issues, and provide group and individual patient education. On average, pharmacists work 2 days per week per site.

The main outcome measures to determine if PAD by primary care pharmacists to prescribers was feasible were number and percentage of prescribers detailed within 3 and 6 months; time for pharmacists to be trained in SC academic detailing; time for a PAD session; time for the PAD coordinator to train the pharmacists; and number of new patient referrals by the prescribers for SC at 3 and 6 months. This was a descriptive cohort feasibility study in 2 primary care–based FHTs consisting of approximately 139 physicians, 10 nurse practitioners (NPs), 250,000 patients, and 5.8 full-time equivalent (FTE) pharmacists. One FHT is a community FHT with more than 40 different clinical sites and the other is an academic FHT with 2 different sites. In the community FHT, approximately 20 of the sites have pharmacists integrated within the offices. At these sites, pharmacists see patients for 30 to 60 minutes to review medications and discuss drug-related issues with the prescribers. On average, pharmacists work in the clinics for at least half a day per week per physician. In the academic FHT, there are approximately 15 family physicians per 1.0 FTE pharmacist. Pharmacists are responsible for teaching residents, and provide group and individual patient education. On average, pharmacists work 2 days per week per site.

Pharmacists integrated within the FHTs who were willing to be trained in academic detailing and FHT family physicians and NPs who were already working collaboratively with integrated pharmacists and who were willing to receive academic detailing services were included in this study.

The intervention included 3 components: a training workshop on basic academic detailing, education on SC content, and PAD sessions with the FHT prescribers.

**Academic detailing basic training workshop**
All pharmacists participated in a 3.5-day basic academic detailing workshop led by a world expert in academic detailing and facilitated by members of the Canadian Academic Detailing Collaboration. Two weeks before the workshop, readings were sent to the participants. The workshop included didactic lectures and role playing to teach the basic skills and knowledge required for effective academic detailing sessions. The program content included an overview of academic detailing, structure for academic detailing visits, introductions to academic detailing visits, physicians speaking about the pressures of current practice, discussion of trust...
and credibility, getting clear objectives and preparing key messages, management and use of detailing aids, challenging responses, closing the communication loop, preparing for a complete academic detailing visit, and a “live” visit. At the end of the workshop, each participant performed a detailing visit for management of sore throat that was video recorded for self-assessment.

**Pharmacist SC training**

Smoking cessation reading materials were provided to the pharmacists 2 weeks before the SC training session. At the training session, the pharmacists were provided with a summary of the reading materials via PowerPoint presentation and handouts. The academic detailing–trained pharmacists reviewed an evidence-based, 2-page SC handout (created by the RxFiles program) that was to be given to the prescribers. Five key messages were emphasized: that caution should be used when prescribing varenicline for patients with psychiatric disorders; that combination therapy of bupropion and nicotine replacement therapy might be considered; that nicotine inhalers and lozenges are available in Canada; that nortriptyline can be used for SC; and that patients should be referred to pharmacists for SC therapy. Each pharmacist practiced academic detailing of SC with his or her colleagues.

The SC training was conducted by the academic detailing coordinator (M.J.)—a pharmacist with a doctorate in pharmacy and previous experience and training in academic detailing from the RxFiles program in Saskatoon, Sask. The academic detailing coordinator organized the basic academic detailing workshop, selected the topic, provided the SC training session materials, identified the key messages, and provided the SC education.

**Patient-specific academic detailing session with prescribers**

Pharmacists were encouraged to book 20-minute one-on-one sessions with each prescriber in their practices to review the 5 key SC messages and discuss the messages in relation to an actual patient in the prescriber’s practice. Patients were identified by chart audits or specific cases that prescribers or pharmacists recalled during the academic detailing discussion.

Patients were referred to pharmacists for SC counseling after being identified through chart audits, during regular appointments (that were not necessarily for SC), or after calling to book appointments for SC. Smoking cessation counseling comprised a 30- to 60-minute appointment between the pharmacist and the patient, during which the pharmacist provided the risks and benefits of each SC product and helped the patient choose a product. Pharmacists also consulted the prescriber regarding therapeutic recommendations for SC, and followed up with each patient and prescriber as required. Pharmacists noted patients’ progress in their medical charts during each visit.

Pharmacists documented how many patients were referred to them for SC counseling by each physician by counting the number of patients referred using the clinic appointment schedule. The total number of referrals per pharmacist was collected by the coordinator at 3 and 6 months.

The main outcomes of the study were based on 4 recognized categories deemed useful to examine when planning feasibility or large-scale studies: processes employed, resources used, management considerations, and scientific metrics. The main outcomes were the number and percentage of prescribers who received PAD within 3 and 6 months (processes); average time for pharmacists to be trained in SC detailing (resources); average time for a PAD session (resources); time for the academic detailing coordinator to train the pharmacists (management); and number of new patient referrals by prescribers for SC counseling at 3 and 6 months after the PAD session (scientific). The feasibility criteria were based on an overview of Canadian academic detailing programs.

Secondary outcomes were the comparison of new patient referrals to pharmacists for SC counseling 6 months before and 6 months after the PAD session; administrative time; location and type of PAD encounter; and tools used (eg, RxFiles handout, PowerPoint presentation, e-mail updates).

This feasibility study aimed for a sample of approximately 20 prescribers; it was expected that this sample size would provide a reasonable opportunity to assess success of the main outcomes. Formal sample-size calculations for prescribers and patients were not carried out.

Data were collected prospectively by the pharmacists and the academic detailing coordinator using structured data collection forms as part of a quality assurance program. Retrospective data collection was conducted to obtain data required to measure the main outcomes. The coordinator also met with each pharmacist to collect any missing data. Data were analyzed using appropriate descriptive statistics: means and SDs or medians and minimum and maximum values for continuous variables, and counts (percentages) for categorical variables.

This study was approved by the McMaster University Faculty of Health Sciences Research Ethics Board.

**RESULTS**

**Characteristics of participants**

All pharmacists (n=8; 5.8 FTE) and 57 of 64 eligible prescribers consented to participate in the study.
Within 4 months of attending the basic academic detailing workshop, all pharmacists were trained in SC education and PAD. Table 3 summarizes the results and analysis of the main outcomes.

**Processes employed**
Pharmacists held their first PAD sessions during a 6-month period. At 3 and 6 months after the first PAD session, 42 of 54 (77.8%) physicians and 8 of 10 (80.0%) NPs, and 48 of 54 (88.9%) physicians and 9 of 10 (90.0%) NPs, respectively, had received PAD on SC.

**Resources used**
The median time for pharmacists to read the SC education package was 1 hour (n = 7 pharmacists; minimum 1 hour, maximum 3 hours). The PAD training session included a PowerPoint presentation (1 hour) and observing a mock PAD session (30 minutes). One pharmacist was unable to attend and received training via e-mail and telephone. Two of 7 pharmacists reported completing additional research to supplement the provided SC educational materials (1 and 2 hours of additional readings, respectively).

### Table 1. Characteristics of pharmacists

<table>
<thead>
<tr>
<th>CHARACTERISTIC</th>
<th>VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of pharmacists</td>
<td>8</td>
</tr>
<tr>
<td>Total FTE (minimum, maximum)</td>
<td>5.8 (0.2, 1.0)</td>
</tr>
<tr>
<td>Highest level of education completed</td>
<td></td>
</tr>
<tr>
<td>• No. with a doctorate of pharmacy</td>
<td>3</td>
</tr>
<tr>
<td>• No. with a bachelor of science in pharmacy</td>
<td>5</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>• No. of men</td>
<td>1</td>
</tr>
<tr>
<td>• No. of women</td>
<td>7</td>
</tr>
<tr>
<td>Years practising as a pharmacist, median (minimum, maximum)</td>
<td>19 (6, 35)</td>
</tr>
<tr>
<td>Years practising in an FHT, median (minimum, maximum)</td>
<td>1.0 (0.4, 2.5)</td>
</tr>
<tr>
<td>No. of physicians per pharmacist, median (minimum, maximum)</td>
<td>7 (3, 11)</td>
</tr>
<tr>
<td>No. of NPs per pharmacist, median (minimum, maximum)</td>
<td>1.5 (0.0, 2.0)</td>
</tr>
</tbody>
</table>

FHT—family health team, FTE—full-time equivalent, NP—nurse practitioner.

---

**Figure 1. Flow diagram of participant inclusion**

Assessed for eligibility (n = 64)
- Family physicians (n = 54)
- NPs (n = 10)

Allocated to intervention (n = 57)
- Received allocated intervention (n = 57)
  - Family physicians (n = 48)
  - NPs (n = 9)

Analyzed (n = 57)
- Family physicians (n = 48)
- NPs (n = 9)

Excluded (n = 7)
- Declined to participate (n = 2 family physicians)
- Unable to schedule appointment (n = 2 family physicians)
- No longer with the FHT and cannot be contacted (n = 3; 2 family physicians and 1 NP)

Enrolment

Allocation

Analysis

FHT—family health team, NP—nurse practitioner.
Table 2. Characteristics of prescribers

<table>
<thead>
<tr>
<th>CHARACTERISTICS</th>
<th>FPs</th>
<th>NPs</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of prescribers</td>
<td>48</td>
<td>9</td>
</tr>
<tr>
<td>Years since graduation, mean (minimum, maximum; SD)</td>
<td>25 (6, 46; 9.5)</td>
<td>7 (1, 13; 4.4)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Male</td>
<td>25</td>
<td>1</td>
</tr>
<tr>
<td>• Female</td>
<td>23</td>
<td>8</td>
</tr>
</tbody>
</table>

Table 3. Results and analysis of main feasibility outcomes

<table>
<thead>
<tr>
<th>MAIN FEASIBILITY OUTCOMES</th>
<th>RESULTS</th>
<th>CRITERIA FOR SUCCESS</th>
<th>WERE CRITERIA FOR SUCCESS MET?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescribers had PAD sessions within 3 and 6 mo</td>
<td>3 mo: 50 of 64 (78.1%)</td>
<td>3 mo: &gt; 50% 6 mo: &gt; 70%</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>6 mo: 57 of 64 (89.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median time for education</td>
<td>Total: 3.1 h (minimum 1.7, maximum 6.2)</td>
<td>&lt; 20 h</td>
<td>Yes</td>
</tr>
<tr>
<td>Median time for PAD sessions</td>
<td>Initial visit: 15 min (minimum 5, maximum 60)</td>
<td>Initial visit: &lt; 60 min Follow-up visit: &lt; 30 min</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Follow-up visit: 25 min (only 1 follow-up visit recorded)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total time for the PAD coordinator to train pharmacists</td>
<td>29.1 h</td>
<td>&lt; 40 h</td>
<td>Yes</td>
</tr>
<tr>
<td>No. of new patient referrals by prescribers for SC counseling at 3 and 6 mo after initial PAD sessions</td>
<td>3 mo: 11 patients per 1.0 FTE pharmacist (total 66 patients) 6 mo: 34 patients per 1.0 FTE pharmacist (total 200 patients) Minimum 0, maximum 77</td>
<td>3 mo: 5 patients per 1.0 FTE pharmacist (total 29 patients) 6 mo: 10 patients per 1.0 FTE pharmacist (total 58 patients)</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Management considerations

The PAD coordinator prepared the reading package (1 hour), handouts (1 hour), and key messages (6 hours); updated the RxFiles handout (2 hours); reviewed additional research (eg, attended local continuing education events; reviewed MEDLINE, Health Canada, and US Food and Drug Administration resources) (6 hours); provided SC PAD training (3 hours); updated the pharmacists via e-mail (6 minutes); and completed 10 hours of PAD training to the pharmacists for a total workload of 29.1 hours.

Scientific metrics

Overall, 6 months after the SC PAD sessions, there were 200 referrals to pharmacists for SC: the number of referrals per pharmacists ranged from 0 to 77 (Figure 2). One

Figure 2. Number of SC referrals by pharmacist

FTE—full-time equivalent, PAD—patient-specific academic detailing, SC—smoking cessation.
pharmacist did not receive any referrals, as the clinic decided to refer the patients to the NP for SC counseling (n=3 patients referred).

Secondary outcomes
Six months before the PAD sessions, 5 of 8 pharmacists (62.5%) had no SC referrals (Figure 2). Most of the PAD encounters occurred in the physicians’ offices (42 of 57, 73.7%), most were one-on-one (46 of 57, 80.7%), and all used the RxFiles handout. The median times for discussion with each prescriber and for administrative tasks were 15 minutes (minimum 5, maximum 60) and 25 minutes (minimum 5, maximum 60), respectively.

DISCUSSION
The results from the study demonstrate that PAD is feasible with respect to the process, resources, management, and scientific components considered to implement and evaluate the intervention. Compared with other existing Canadian academic detailing programs, there was a higher participation rate among prescribers and similar administration times for the PAD coordinator and pharmacists.44 The high number of referrals to the pharmacists for SC after the provision of PAD shows that PAD might be a promising approach that moves beyond knowledge transmission to use existing clinical relationships and changes to processes within the practice setting to stimulate substantial behaviour changes. In PAD, pharmacists in primary care might also require less administrative time compared with conventional academic detailers, as there is less travel to offices and no waiting time in offices.

Although the clinical effect of SC counseling is not examined in this study, more referrals for specific SC activities increase the potential for more patients to quit smoking. Patients who receive brief advice on SC from their physicians are more likely to quit smoking compared with those who receive usual care (relative risk 1.66, 95% CI 1.42 to 1.94).45 More intensive interventions by physicians produced a higher quit rate in patients than usual care did (relative risk 1.84, 95% CI 1.60 to 2.13).45 Patient-specific academic detailing might enhance SC rates, as both prescribers and pharmacists are actively assisting patients with SC. Ideally, at all visits prescribers would ask patients whether they smoked and whether they wanted to quit. If patients indicated they wanted to quit, then prescribers would refer patients to pharmacists for initial SC counseling visits. Pharmacists would consult the prescribers regarding SC medication prescriptions and follow up with patients and prescribers as required.

Limitations
Some limitations of this study include recall and selection bias. While most of the data were collected prospectively as part of a quality assurance program, some of the training times for pharmacist and physician encounters were collected retrospectively. Selection bias might be present, as this feasibility study was completed within 2 FHTs; the results might not reflect other FHTs or primary care sites. Also, prescribers volunteered to receive academic detailing and the results of this feasibility study might not reflect those participants who declined. Given that this was a feasibility study, another limitation includes the lack of data on actual quit rates of patients following the introduction of the PAD program.

Conclusion
The results of this study can be used to plan a larger PAD study on SC in an environment where policies would encourage such a program. As of August 2010, there were 200 FHTs in Ontario, in which 90 different FHTs had approximately 132 pharmacists integrated within the practices.46 A large, multisite, prospective randomized study of PAD on SC would be optimal to better understand how this approach can improve medication prescribing, its effectiveness on quit rates, and related patient health outcomes.

This study shows that PAD is feasible in a primary care setting. Further study is warranted to determine the effectiveness of PAD and whether PAD is more effective than conventional academic detailing.

Dr Jin is a clinical pharmacist and Coordinator of the Academic Detailing Program for the Hamilton Family Health Team in Ontario. Dr Gagnon is Pharmacy Program Manager for the Hamilton Family Health Team. Dr Levine is Director of the Centre for Evaluation of Medicines at the Father Sean O’Sullivan Research Centre at St Joseph’s Hospital in Hamilton, is Professor in the Department of Clinical Epidemiology and Biostatistics at McMaster University, and is a consultant physician in Internal Medicine and Clinical Pharmacology at St Joseph’s Hospital and Hamilton Health Sciences. Dr Thabane is Professor of Biostatistics and Associate Chair of the Department of Clinical Epidemiology and Biostatistics at McMaster University, and Director of Biostatistics at St Joseph’s Healthcare Hamilton. Ms Rodriguez is Research Coordinator in the Department of Family Medicine at McMaster University. Dr Dolovich is Research Director and Associate Professor in the Department of Family Medicine at McMaster University, and Scientist and Associate Director in the Centre for Evaluation of Medicines at St Joseph’s Healthcare Hamilton.

Contributors
Dr Jin contributed to the concept and design of the study; acquisition, analysis, and interpretation of data; drafting the article; and final approval of the version to be published. Dr Gagnon contributed to acquisition of data, critical revision of the article for important intellectual content, and final approval of the version to be published. Ms Rodriguez contributed to the design of the study, interpretation of data, critical revision of the article for important intellectual content, and final approval of the version to be published. Dr Levine contributed to the design of the study, interpretation of data, critical revision of the article for important intellectual content, and final approval of the version to be published. Ms Rodriguez contributed to the design of the study, critical revision of the article for important intellectual content, and final approval of the version to be published. Dr Thabane contributed to the concept and design of the study; acquisition, analysis, and interpretation of data; critical revision of the article for important intellectual content, and final approval of the version to be published.

Competing interests
No conflict of interest
De Burgh S, Mant A, Mattick RP, Donnelly N, Hall W, Bridges-Webb C. A

Stafford RS, Bartholomew LK, Cushman WC, Cutler JA, Davis BR, Dawson

Sheffer MA, Baker TB, Fraser DL, Adsit RT, McAfee TA, Fiore MC. Fax refer-


Coenen S, Van Royen P, Michiels B, Denekens J. Optimizing antibiotic pre-

Berings D, Blondeel L, Habraken H. The effect of industry-independent drug

Van Eijk ME, Avorn J, Porsius AJ, de Boer A. Reducing prescribing of highly

Floor, Hamilton, ON L8P 1C8; telephone 905 667-4867, extension 311; e-mail

Correspondence

References


2. Seager JM, Howell-Jones RS, Dunstan FD, Lewis MA, Richmond S, Thomas


4. Academic detailing to improve use of broad-spectrum antibiotics at an aca-

general practitioner prescribing of antibiotics by use of a ther-


8. Van Eijk ME, Avorn J, Porsius AJ, de Boer A. Reducing prescribing of highly


10. De Burgh S, Mant A, Mattick RP, Donnelly N, Hall W, Bridges-Webb C. A


13. Optimal Therapy Initiative. Smoking cessation guidelines. How to treat

14. Young JM, D Este C, Ward JE. Improving family physicians’ use of evidence-

15. Schmidt I, Claessen CB, Westerholm B, Billing LS, Svarstad BL. The impact of

16. Young JM, D Este C, Ward JE. Improving family physicians’ use of evidence-

17. Schauer GL, Thompson JR, Zbikowski SM. Results from an outbreak pro-

18. Schaffer MA, Baker TB, Fraser DL, Adsit RT, McAfee TA, Fiore MC. Fax refer-

19. Adsit R, Fraser D, Redmond L, Smith S, Fiore M. Changing clinical prac-


23. Allen M, Ferrier S, O’Connor N, Fleming I. Family physicians’ perception of aca-


29. Avorn J, Soumerai SB. Improving drug-therapy decisions through educa-
tional outreach: A randomized controlled trial of academically based “detail-

30. May FW, Rowett DS, Gilbert AL, McNeece J, Hurley E. Outcomes of an educational-outreach service for community medical practitioners: non-

31. Freemantle N, Nazareth I, Eccles M, Wood J, Haines A. Evidence-based Outcome Trialists. A randomized controlled trial of the effect of edu-


33. Bisco AL, Gerber MA, Gualtney MJ Jr, Kaplan EL, Schwartz RH, Infectious Diseases Society of America. Practice guidelines for the diagnosis and man-


35. Singh S, Dolan JG, Centor RM. Optimal management of adults with pharyn-


41. Crane R. The most addictive drug, the most deadly substance: smoking ces-


46. Ontario Ministry of Health and Long-Term Care. Family health teams. 

**Patient-specific academic detailing for smoking cessation | Research**